17 citations
,
December 1997 in “Transplantation” Tacrolimus can cause hair loss in kidney transplant patients.
30 citations
,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
3 citations
,
July 2025 in “International Immunopharmacology”
December 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Flutamide, an oral anti-androgen therapy, is effective in treating female pattern hair loss, even without systemic androgen excess.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
3 citations
,
May 2019 in “Journal of Cosmetic Dermatology” Miliacin with polar lipids helps hair growth and improves hair loss in women.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
February 2021 in “European Chemical Bulletin” A reliable method was developed to measure Minoxidil and Finasteride accurately in medicines.
February 2024 in “Scientific Reports” Topical minoxidil and dietary supplements improved hair regrowth in children with hair loss from chemotherapy.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
May 2018 in “Más dermatología” The higher dose supplement was more effective in treating female hair loss.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
109 citations
,
September 1999 in “Archives of Dermatology” Combining fluticasone propionate and UV-A is more effective for vitiligo than using either alone.
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
12 citations
,
June 2024 in “JAAD Case Reports” Tirzepatide may improve hair loss by reducing insulin resistance.
Individualized treatments may help manage Dercum's disease symptoms.
1 citations
,
March 2018 in “Journal of lasers in medical sciences” Combining capislow with laser is more effective for reducing unwanted hair, but the effect is temporary.
July 2004 in “Journal of Clinical Oncology” Isolated limb perfusion is a safe and effective treatment for limb melanoma.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
March 2026 in “SKIN The Journal of Cutaneous Medicine” All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
February 1990 in “Journal of The American Academy of Dermatology” New skin treatments in 1987-1988 showed effectiveness for various conditions, but some had side effects or risks.
September 2025 in “Clinical Case Reports” Oral minoxidil can cause dry mouth, but switching to topical minoxidil may prevent this side effect.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
July 2026 in “Frontiers in Pediatrics” An 11-year-old girl with severe hair loss regrew and repigmented her hair after JAK inhibitor treatment.
61 citations
,
December 2021 in “Frontiers in Cell and Developmental Biology” Vitiligo treatments are improving but still face challenges and high relapse rates.
July 2026 in “Journal of the American Academy of Dermatology”